Hepatocarcinogenesis Is Supported by Sublethal Necroptosis Signaling
NF-κB activation in hepatocytes with low RIPK3 expression can trigger sublethal necrosome activation.
NF-κB activation in hepatocytes with low RIPK3 expression can trigger sublethal necrosome activation.
This site uses cookies. By continuing to use our website, you are agreeing to our privacy
Major Finding: A pan-cancer resource was developed that identifies the presence and relevance of the metastatic microbiome. Approach: Multi-omic analyses were conducted on 4,160 metastatic…
Major Finding: IDH-mutant low-grade gliomas that respond to IDH inhibition undergo lineage differentiation. Concept: Glioma cell fate is shifted towards differentiation and away from a…
Summary:. Rosano, Sofyali, Dhiman, and colleagues show that epigenetic-related changes occur in endocrine therapy (ET)-induced dormancy in estrogen receptor positive (ER+) breast cancer, as well…
Major Finding: Nonmalignant BRCA1/BRCA2-mutant breast tissues exhibit markers of immune infiltration and exhaustion. Approach: A single-cell atlas of the human breast maps changes influenced by…
Major Finding: Anti-TRBC1 chimeric antigen receptor T-cell activity is limited by fratricide by normal TRBC1+ T cells. Concept: Development of an anti-TRBC1 antibody drug conjugate (ADC) demonstrates…
Abstract. RAF inhibitors have transformed treatment for BRAF V600-mutant cancer patients, but clinical benefit is limited by adaptive induction of ERK signaling, genetic alterations that…
Elizabeth McKenna: We have an opening on the Cancer Discovery team! / American Association for Cancer Research, cancer, Cancer Discovery team, Elizabeth
Paolo Tarantino: HER2 is about to change again / AstraZeneca, Breast Cancer, cancer, Cancer Discovery, DESTINY-Breast06 Trial, Enhertu, HER2-low Breast
Sotorasib and other selected KRASG12C inhibitors leverage differential dependence on switch-II pocket binding at amino acid position 95 to target all RASG12C isoforms, which has…